Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

530 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT.
Gonzalez-Rodriguez AP, Lopez-Corral L, Fajardo DFM, Gonzalez-Huerta AJ, Palomo P, Bermudez A, Ripa TZ, Santos-Diaz P, Gonzalez-Muñiz S, Zanabilli J, Jimenez Ubieto A, de Arriba F, Arnao-Herraiz M, Sordo-Bahamonde C, López-Soto A, Gonzalez S, Rosiñol L, Mateos MV. Gonzalez-Rodriguez AP, et al. Among authors: mateos mv. Bone Marrow Transplant. 2020 Feb;55(2):461-463. doi: 10.1038/s41409-019-0525-1. Epub 2019 Apr 15. Bone Marrow Transplant. 2020. PMID: 30988379 No abstract available.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Mateos MV, et al. Blood. 2006 Oct 1;108(7):2165-72. doi: 10.1182/blood-2006-04-019778. Epub 2006 Jun 13. Blood. 2006. PMID: 16772605 Free article. Clinical Trial.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Mateos MV, et al. Haematologica. 2008 Apr;93(4):560-5. doi: 10.3324/haematol.12106. Epub 2008 Mar 5. Haematologica. 2008. PMID: 18322252 Free article. Clinical Trial.
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF; PETHEMA Study Group; GEM Study Group. Mateo G, et al. Among authors: mateos mv. J Clin Oncol. 2008 Jun 1;26(16):2737-44. doi: 10.1200/JCO.2007.15.4120. Epub 2008 Apr 28. J Clin Oncol. 2008. PMID: 18443352 Clinical Trial.
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF. Mateos MV, et al. Lancet Oncol. 2010 Oct;11(10):934-41. doi: 10.1016/S1470-2045(10)70187-X. Epub 2010 Aug 23. Lancet Oncol. 2010. PMID: 20739218 Clinical Trial.
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.
Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, Alonso L, Oriol A, Teruel AI, de Paz R, Laraña JG, Bengoechea E, Martin A, Mediavilla JD, Palomera L, de Arriba F, Bladé J, Orfao A, Lahuerta JJ, San Miguel JF. Paiva B, et al. Among authors: mateos mv. J Clin Oncol. 2011 Apr 20;29(12):1627-33. doi: 10.1200/JCO.2010.33.1967. Epub 2011 Mar 14. J Clin Oncol. 2011. PMID: 21402611 Clinical Trial.
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.
Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, García-Laraña J, Sureda A, de la Rubia J, Conde E, Martinez R, de Arriba F, Viguria MC, Besalduch J, Cabrera R, Gonzalez-San Miguel JD, Guzman-Zamudio JL, Gomez del Castillo MC, Moraleda JM, García-Ruiz JC, San Miguel J, Lahuerta JJ; Grupo Español de MM; Programa para el Estudio de la Terapé utica en Hemopatía Maligna. Martinez-Lopez J, et al. Among authors: mateos mv. Blood. 2011 Jul 21;118(3):529-34. doi: 10.1182/blood-2011-01-332320. Epub 2011 Apr 11. Blood. 2011. PMID: 21482708 Free article.
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
Mateos MV, Gutiérrez NC, Martín-Ramos ML, Paiva B, Montalbán MA, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Martín A, Díaz-Mediavilla J, de Arriba F, Palomera L, Hernández JM, Sureda A, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, Fernández M, García-Sanz R, Vidriales MB, Bladé J, Lahuerta JJ, San Miguel JF. Mateos MV, et al. Blood. 2011 Oct 27;118(17):4547-53. doi: 10.1182/blood-2011-04-345801. Epub 2011 Sep 6. Blood. 2011. PMID: 21900193 Free article. Clinical Trial.
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.
Paiva B, Gutiérrez NC, Rosiñol L, Vídriales MB, Montalbán MÁ, Martínez-López J, Mateos MV, Cibeira MT, Cordón L, Oriol A, Terol MJ, Echeveste MA, de Paz R, de Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Sureda A, Gorosquieta A, Alegre A, Martin A, Hernández MT, Lahuerta JJ, Bladé J, San Miguel JF; PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study Groups. Paiva B, et al. Among authors: mateos mv. Blood. 2012 Jan 19;119(3):687-91. doi: 10.1182/blood-2011-07-370460. Epub 2011 Nov 29. Blood. 2012. PMID: 22128143 Free article. Clinical Trial.
Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
Matarraz S, Paiva B, Diez-Campelo M, López-Corral L, Pérez E, Mateos MV, Giraldo P, Hernández MT, San Miguel JF, Orfao A; GEM Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Co-operative Study Groups. Matarraz S, et al. Among authors: mateos mv. Haematologica. 2012 Oct;97(10):1608-11. doi: 10.3324/haematol.2012.064121. Epub 2012 Apr 17. Haematologica. 2012. PMID: 22511492 Free PMC article.
530 results